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A B S T R A C T
Two oxidovanadium(IV) complexes carrying Schiﬀ base ligands obtained from the condensation of 4,5-di-
chlorobenzene-1,2-diamine and salicylaldehyde derivatives were synthesised and characterised, including their
X-ray crystallographic structures. They were evaluated as dipeptidyl peptidase IV (DPP-IV) inhibitors for the
treatment of type 2 diabetes. These compounds were moderate inhibitors of DPP-IV, with IC50 values of ca.
40 μM. In vivo tests showed that complexes 1 and 2 could lower signiﬁcantly the level of glucose in the blood of
alloxan-diabetic mice at doses of 22.5 mg V·kg−1 and 29.6 mg V·kg−1, respectively. Moreover, molecular
modeling studies suggested that the oxidovanadium complexes 1 and 2 could ﬁt well into the active-site cleft of
the kinase domain of DPP-IV. To the best of our knowledge, this is the ﬁrst report of vanadium complexes
capable of inhibiting DPP-IV.
1. Introduction
Type 2 diabetes is a metabolic disease characterised by insulin re-
sistance, hyperglycemia and hyperlipidemia. Dipeptidyl peptidase IV
(DPP-IV) inhibitors are a new type of oral hypoglycemic agents for the
treatment of patients with type 2 diabetes [1]. Inhibition of the enzyme
DPP-IV results in decreased degradation of both glucagon-like peptide-1
(GLP-1) and glucose-dependent insulinotropic peptide (GIP)·Through
action via GLP-1 and GIP, DPP-IV inhibitors can enhance insulin se-
cretion, control the level of glucose in blood and protect the function of
β-cells [2,3]. Consequently, inhibition of DPP-IV is rapidly emerging as
a novel therapeutic approach for the treatment of type 2 diabetes, and
potent DPP-IV inhibitors have recently been reported [4–7]. A number
of X-ray structures of co-crystals of inhibitors and the DPP-IV enzyme
have been reported, providing important structural information [8–11].
Vanadium compounds have long been recognised as phosphatase
inhibitors, since vanadates are structurally similar to phosphates [12].
Numerous studies have demonstrated that vanadium compounds have
insulin-enhancing eﬀects and can improve the symptoms of diabetes in
a variety of animal models [13–17]. Vanadyl sulfate and sodium me-
tavanadate have been used in studies with human diabetic patients
resembling phase II clinical trials [18–24]. These compounds showed
moderate success in alleviating some of the symptoms of diabetes. Due
to their wide availability as nutritional supplements they did not go
through Phase I clinical trials. Additionally, the chelated complex bis
(ethylmaltolato)oxidovanadium(IV) (BEOV) completed Phase I trials
and a Phase IIa trial. Clinical trials were discontinued following further
pre-clinical safety testing, in which it became clear that renal compli-
cations could be precipitated without any obvious warning signs, at
slightly higher concentrations than were tried in human volunteers
[25–27]. It has been reported that vanadium compounds exert insulin-
enhancement eﬀects and cell protection via a multiple mechanism in-
volving inhibition of protein-tyrosine phosphatase 1B (PTP1B), activa-
tion of peroxisome proliferator-activated receptor (PPARs) – AMP-ac-
tivated protein kinase (AMPK) signaling, and regulation of unfolded
protein responses (UPRs) [28]. Vanadium complexes carrying
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tridentate Schiﬀ base ligands selectively inhibit PTP1B, and oxidova-
nadium compounds carrying mixed ligands are highly potent (nano-
molar activity) competitive inhibitors for PTP1B [29–31]. Additionally,
vanadium complexes have also been shown to inhibit human islet
amyloid polypeptide (hIAPP) aggregation [32]. However, the me-
chanism of action of vanadium complexes ultimately leading to the
observed insulin-sensitizing eﬀects is not well understood [33–35].
Therefore, studying their role as enzyme inhibitors and their inﬂuence
on glucose metabolism is of fundamental importance.
There appear to be no reports exploring the possible role of vana-
dium or other antidiabetic metal complexes as DPP-IV inhibitors. In this
paper, we report two novel oxidovanadium complexes carrying Schiﬀ
base ligands obtained from the condensation of 4,5-dichlorobenzene-
1,2-diamine and 4-R-salicylaldehyde (where R1 = H or diethylamine)
that have been designed and synthesised as potential DPP-IV enzyme
inhibitors. Their biological activity has been assessed by blood glucose-
lowering assays, and their interaction with DPP-IV explored by bio-
chemical assays using recombinant DPP-IV and molecular modeling.
2. Experimental
2.1. Materials and methods
All reagents and solvents were purchased commercially as reagent
grade and used without further puriﬁcation unless otherwise stated.
Double-distilled water was used to prepare buﬀer solutions. Vanadyl
sulfate hydrate was purchased from the Sigma-Aldrich Chemical Co.,
and EPR tubes from Wilmad Labglass.
2.2. Preparation of oxidovanadium complexes
The synthetic routes are shown in Scheme 1.
2.2.1. Preparation of [(1E,1′E)-N,N′-(4,5-dichloro-1,2-phenylene)- bis(1-
(2-(λ1-oxidanyl)phenyl)methanimine)] oxidovanadium (IV) (1)
Salicylaldehyde (0.94 g, 5 mmol) dissolved in ethanol was added
dropwise to 4,5-dichloride-1,2-phenylenediamine (3 mmol, 0.51 g) in
ethanol at room temperature. The mixture was gradually heated to
333 K and maintained at this temperature for 4 h. Then VOSO4·5H2O
(1 mmol, 0.254 g) was added to this solution. The mixture was stirred
for about 30 min. The green precipitate was collected and dissolved in
dimethyl sulfoxide (DMSO)/dichloromethane (2:1 v/v). Crystals sui-
table for X-ray diﬀraction were obtained by slow diﬀusion of ether into
DMSO/dichloromethane (2:1 v/v) solution of the product at 277 K.
Yield: 56.5%.
Anal. Calcd. for C20H12Cl2N2O3V: %C, 53.3; %H, 2.7; %N, 6.2. Found:
%C, 53.6; %H, 2.4; %N, 6.6. UV–vis (DMSO) λmax = 310 nm
(ε= 14,847 L·mol−1·cm−1), 325 nm (ε=17,844 L·mol−1·cm−1),
340 nm (ε= 18,204 L·mol−1·cm−1), 370 nm (ε= 5707 L·mol−1·cm−1),
415 nm (ε= 3868 L·mol−1·cm−1). IR (KBr disk): ν (cm−1) = 1601
(νc = N), 965 (νv = o), 598 (νv − o).
2.2.2. Preparation of [4,4′-((1E,1′E)-((4,5-dichloro-1,2-phenylene)bis
(azanylylidene))- bis(methanylylidene))bis(N,N-diethyl-3-(λ1-oxidanyl)
aniline)]-oxidovanadium(IV) DMSO (2)
4-(Diethylamino)salicylaldehyde (9 mmol, 1.85 g) dissolved in
ethanol (15 mL) was added dropwise to 4,5-dichloride-1,2-phenylene-
diamine(3 mmol, 0.51 g) in ethanol (30 mL) at room temperature. The
mixture was gradually heated to 333 K and maintained at this tem-
perature for 4 h. Then VOSO4·5H2O (1 mmol, 0.254 g) was added into
this solution. The mixture was stirred for about 30 min. The green-
yellow precipitate was collected and dissolved as before. Crystals sui-
table for X-ray diﬀraction were obtained by slow diﬀusion of ether into
a DMSO solution of the product at 277 K. Yield: 45.4%.
Anal. Calcd. for C28H30Cl2N4VO3·DMSO: %C 53.7, %H 5.4, %N 8.4.
Found: %C, 53.3; %H, 5.5; %N, 8.6. UV–vis (DMSO) λmax = 376 nm
(ε= 4104 L·mol−1·cm−1), 396 nm (ε= 5363 L·mol−1·cm−1), 448 nm
(ε= 7793 L·mol−1·cm−1). IR (KBr disk): ν (cm−1) = 1655 (νc = N),
978 (νv = o), 567 (νv − o).
2.3. X-ray crystallography
X-ray diﬀraction data for complexes 1 and 2 were collected at 298 K
using a Bruker Smart Apex II CCD detector with graphite mono-
chromator (ω scan, 2θmax = 56.46) Mo Ka radiation. For complex 1, a
total of 12,051 reﬂections were collected, with 4252 reﬂections being
unique. For complex 2, a total of 17,511 reﬂections were collected, with
5573 reﬂections being unique. The crystal structures of 1 and 2 were
solved by direct method SHLXS-97 (Sheldrick, 1990) and expanded
using diﬀerence Fourier technique, reﬁned by the program SHLXL-97
(Sheldrick, 1997) and the full-matrix least-squares calculations. The
crystal data and structure reﬁnements are given in Table 1.
2.4. IR spectroscopy
Infrared spectra were recorded as KBr pellets in the range
4000–400 cm−1 on a Perkin-Elmer Paragon 1000 Fourier-transform
spectrometer.
2.5. EPR spectroscopy
EPR spectra were recorded at ambient temperature on a Bruker EMX
(X-band) spectrometer. Liquid samples were contained in quartz ca-
pillary (I.D. 1.0 mm; O.D. 1.2 mm; Wilmad Labglass) sealed with T-Blu
Tac®, placed inside larger quartz tubes (O.D. 2.0 mm) to achieve easy
and accurate positioning of the sample inside the resonator.
Measurements were made on DMF solutions or on powders at 300 K.
Data were ﬁtted using the Easyspin version 5.1.9 software [36].
2.6. DPP-IV inhibition assay
Recombinant DPP-IV was mixed with diﬀerent concentrations of
complexes 1 or 2 (45–0.6 μM) in the assay buﬀer (100 mM Tris-HCl,
150 mM NaCl, 1.0 mg/mL BSA, pH 8.2). The enzyme reaction was
started by addition of a glycyl-L-proline-p-nitroanilide tosylate solution
and the change in absorbance at 405 nm was monitored for 30 min
using a microplate reader (Rayto, Rt-6100, China) [37]. Inhibition
constants (IC50) were calculated by ﬁtting the dose-dependent inhibi-
tion curves based on the means of several replicate experiments.
2.7. Molecular modeling
To investigate the binding mode of vanadium complexes 1 and 2 to
the DPP-IV, the advanced docking program Autodock 3.0.3 was used to
dock automatically the inhibitor to the kinase domain of the enzyme.
The crystal structure of the kinase domain of DPP-IV in a complex with
its inhibitor W61 (PDB entry code 3VJM) was recovered from
Brookhaven Protein Database (PDB). The missing atoms and residues
were modeled in Sybyl 6.8.17. Atomic charges were taken as Kollman-
united-atom [38] for the macromolecule and Gasteiger–Marsili [39] for
the inhibitor. To explore the binding mode of compounds to the kinase
domain of DPP-IV, the advanced docking program Autodock 3.0.3 [40]
was used to dock automatically the inhibitor to the kinase domain of
the enzyme. The Lamarckian genetic algorithm (LGA) was applied to
analyze inhibitor–enzyme interactions. A Solis and Wets local search
performed the energy minimization on a user-speciﬁed proportion of
the population. The docked conformations of the inhibitor were gen-
erated after a reasonable number of evaluations. The whole docking
operation in this study can be summarised as follows. First, the kinase
domain of DPP-IV was checked for polar hydrogens and assigned for
partial atomic charges, then a PDBQ ﬁle was created, and the atomic
solvation parameters were assigned for the macromolecule. Meanwhile,
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some of the torsion angles of the inhibitor that would be explored
during molecular docking stage were deﬁned, allowing the conforma-
tion search for the ligand during the docking process. Second, the grid
map with 60 × 60 × 60 points and a spacing of 0.375 Å was calculated
using the AutoGrid program in order to evaluate the binding energies
between the inhibitor and the macromolecule. Third, some important
parameters for LGA calculations were reasonably set (see Box 1), not
only the atom types, but also the generations and the number of runs for
the LGA algorithm were edited and properly assigned according to the
requirements of the Amber force ﬁeld. The maximum number of gen-
erations, energy evaluations and docking runs were set to 3.0 × 105,
1.5 × 107, and 30, respectively. Finally, the docked complex of the
inhibitor–enzyme for the inhibitor was selected according to the cri-
terion of interaction energy combined with geometrical matching
quality.
Additionally, to identify the binding sites in DPP-IV, the grid size
was set to 100 × 100 × 100 points along the X-, Y-, and Z-axes with a
0.375 Å grid spacing. Docking simulations were performed using the
Lamarckian genetic algorithm (LGA) and the Solis and Wets local
search method. Each run of the docking operation was terminated after
a maximum of 2,500,000 energy evaluations.
Scheme 1. Synthesis of oxidovanadium complexes 1 and 2.
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2.8. Glucose modulation studies
Male ICR mice weighting 25–30 g were obtained from Chengdu
Dossy Experimental Animals Co. Ltd. Sichuan, China. Mice were al-
lowed free access to standard solid food for laboratory animals and tap
water. Diabetic mice were generated by a single intraperitoneal injec-
tion of alloxan 65 mg·kg−1 in 0.9% saline. Alloxan is known to induce
diabetes in treated animals by destroying pancreatic β-cells through the
generation of reactive oxygen species [41]. Therefore, it can be used as
an animal model for type 1 diabetes, but also for advanced stages of
type 2 diabetes. Four days after alloxan injection, blood samples for
analysis of blood glucose were obtained from the tail vein of the mice
and the blood glucose were measured by the glucose oxidase method.
The alloxan-mice with the blood glucose levels ≧ 11.1 mM were con-
sidered as diabetic. Normal mice were injected with 0.9% saline alone.
The experimental animals were randomly divided into four groups
with ten mice each. Diabetic control group: alloxan-diabetic mice
treated with 0.9% saline; positive groups: alloxan-diabetic mice treated
with 250 mg·kg−1 metformin; treated diabetic group: alloxan-diabetic
mice treated with complex 1 22.5 mg V·kg−1 (intragastric administra-
tion; ig) and 2 29.6 mg V·kg−1 (ig) dissolved in 0.5% sodium carbox-
ymethyl cellulose (CMC-Na). The substances above were administered
intragastricly once a day at the volume of 10 mL·kg−1 for 3 weeks.
Once per week the blood samples were collected from the tail vein of
the mice for the blood glucose assay.
Statistics values were presented as means ± standard deviations.
Statistical analysis was performed by one-way analysis of variance
followed by Dunnett's multiple comparison tests using Prism version 4.0
software.
3. Results and discussion
3.1. Synthesis and the X-ray crystal structure
Vanadyl complexes 1 and 2 were synthesised by the routes shown in
Scheme 1. The X-ray crystal structures of complexes 1 and 2 (Fig. 1)
show that they are structurally similar to related complexes described
previously [42,43]. Bond lengths and angles around the vanadium
centre are shown in Tables S1 and S2.
Similarly to other VO(salen) compounds [44,45], complexes 1 and 2
are best described as having closely square-pyramidal geometry, be-
cause of their τ values of 0.06 and 0.05. The τ parameter measure the
distortion of a square-pyramidal structure toward trigonal bipyramidal
[46]. The basal square plane of 1 and 2 is constituted by the Schiﬀ base
ligand, which acts as a tetradentate ligand through its imine N atoms
and its deprotonated phenolate O atoms. Torsional angles show that
atoms N(1)/N(2)/O(2)/O(3) are approximately in one plane, with O1
atoms located at the axial positions. The V]O bond length is 1.596(6)
Å, which is typical for ﬁve-coordinate vanadyl species, and VeO2 and
VeO3 bond lengths in 1 and 2 are all between 1.9162(17) and 1.944(2)
Å, typical of single bonds. Additionally, the bond angles in the basal
plane are smaller than the vertex angles. This is due to the position of
the vanadium(IV) center, which lies above the basal plane of the
complex (0.6022 Å in 1, and 0.5901 Å in 2).
3.2. Infrared spectroscopy
Vanadium complexes 1 and 2 exhibit a sharp band at ca. 966 cm−1
due to the ν(V]O) mode [47]. The C]N stretching frequencies for the
ligands occur at ca. 1620 cm−1 and are shifted to lower frequencies
(1600–1605 cm−1) in the complexes, indicating the coordination of the
imine nitrogens to vanadium [48].
3.3. UV–visible spectroscopy
The VO-complexes were only moderately soluble in methanol, but
highly soluble in DMSO. The spectra of the ligands show several sharp
absorption maxima in the UV region at approximately 390 nm (ligand
1), and 352 and 400 nm (ligand 2), assignable to π→ π* and n→ π*
transitions (see Fig. S1). Upon complexation, the π→ π* transitions
shifted to longer wavelengths, while the n→ π* transition merged with
an additional broad intense band at approximately 415 (complex 1) and
438 (complex 2) due to ligand-to-metal charge transfer from the phe-
nolate oxygen to empty d orbitals of vanadium.
Table 1
Crystallographic data for complexes 1 and 2.
Compound 1 2
Empirical C20H12Cl2N2O3V C28H32Cl2N4O6SV
Formula weight 450.16 674.48
Temperature (K) 298(2) 298(2)
Wavelength (Å) 0.71073 0.71073
Crystal size (mm) 0.26 × 0.19 × 0.12 0.28 × 0.21 × 0.14
Space group P2(1)/n P2(1)/n
Crystal system Monoclinic Monoclinic
a (Å) 10.4674(11) 16.4371(16)
b (Å) 9.1811(10) 10.1372(10)
c (Å) 18.9133(19) 19.0776(18)
α (°) 90 90
β (°) 95.6180(10) 92.5380(10)
γ (°) 90 90
Volume (Å3) 1808.9(3) 3175.7(5)
Z 4 4
Dcalc (Mg/cm3) 1.653 1.411
Absorption coeﬃcient
(mm−1)
1.372 0.592
F(000) 908 1396
Limiting indices −10≤ h≤ 13
−11≤ k≤ 12
−25≤ l≤ 24
−17≤ h≤ 19,
−12≤ k≤ 12,
−22≤ l≤ 22
Reﬂections collected/
unique
12,051/4252[R(int)
= 0.0369]
17,511/5573[R(int)
= 0.0379]
Completeness to
theta = 25.15
94.40% 100.00%
Reﬁnement method Full-matrix least-squares
on F^2
Full-matrix least-squares
on F2
Absorption correction None None
Data/restraints/
parameters
4252/0/253 5573/0/385
Goodness-of-ﬁt on F2 1.01 1.045
Final R indices
[I > 2σ(I)]
R1 = 0.0399,
wR2 = 0.0957
R1 = 0.0539,
wR2 = 0.1485
R indices (all data) R1 = 0.0660,
wR2 = 0.1090
R1 = 0.0763,
wR2 = 0.1628
Largest diﬀ. peak and
hole(е. Å)
0.307 and −0.306 0.589 and −0.698
Box 1
Vina conﬁguration ﬁle.
receptor = 1iep_receptorH.pdbqt
ligand = 1iep_ligandH.pdbqt
center_x = 15.19
center_y = 53.903
center_z = 16.917
size_x = 15.0
size_y = 17.25
size_z = 15.0
out = 1iep_ligandH_out.pdbqt
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3.4. EPR spectroscopy of VO-complexes
EPR is a useful tool to investigate the nature of the V(IV) centre in
oxidovanadium (IV) complexes [49]. The X-band EPR spectra of the
complexes were recorded as DMF solutions and powder at 298 K (Fig.
S2 and S3). VIVO has a 3d1 outer shell conﬁguration and 51V (99.8%
abundance) has a nuclear spin quantum number I= 7/2 giving rise to
the observed hyperﬁne coupling (8 lines) characteristic of oxidovana-
dium (IV) complexes [50–52]. Furthermore, g0 and A0 values obtained
(1: g0 = 1.972; A0 = 98 G; 2: g0 = 1.974; A0 = 96.6 G) are in ac-
cordance with the correlation previously established for square-pyr-
amidal vanadyl(IV) complexes with equatorial ligand ﬁelds [53].
3.5. DPP-IV inhibition assays by oxidovanadium complexes
DPP-IV is a protein located in the extracellular membrane, but it can
also be found in human plasma as a soluble form lacking the trans-
membrane region [54]. Some of DPP-IV inhibitors are in clinical trials
as a new therapy for non-insulin-dependent diabetes mellitus (Type 2
diabetes). The therapeutic beneﬁt is derived from reduced inactivation
of incretins GLP-1 and GIP by DPP-IV, thus stimulating greater insulin
production, and control the level of glucose in blood in patients with
type 2 diabetes [55,56]. Several studies have investigated the eﬃciency
of drugs for the inhibition of DPP-IV [1], but as yet none has involved V
compounds.
Both complexes were tested for their ability to inhibit DPP-IV using
Gly-Pro-p-nitroanilide as the substrate. The enzyme and complexes
were preincubated for 30 min prior to the initiation of the enzymatic
reaction by the addition of the substrate. IC50 values were obtained by
ﬁtting the dose-dependent inhibition curves and was deﬁned as the
concentration of the complex needed to reduce the activity of the en-
zyme by 50%. The IC50 values for complexes 1 and 2 are very similar,
38 and 45 μM respectively (Table 2), indicating that the presence of the
NEt2 substituent has little eﬀect on the activity of the complexes. These
results indicate moderate inhibition of DPP-IV, although the observed
eﬀect is considerably lower than that of clinically-used sitagliptin.
3.6. Molecular modeling study of the interaction of complexes 1, 2 with
DPP-IV
Molecular docking was performed to explore the possible binding of
complexes 1 and 2 to the kinase domain of DPP-IV. The blind docking
mode with the lowest binding free energy is shown in Figs. 2–3, and
S4–S5. The interaction energies between amino residues and complexes
1 and 2 are listed in Tables S3 and S4.
Figs. 2 and S4 show that complex 1 is buried at one end of the active
site of the kinase domain of the DPP-IV enzyme. Hydrogen bonds are
formed in the active site between the axial oxygen from the oxidova-
nadium moiety and Asn 710, and one of the hydroxyl groups from the
salicylaldimine moieties and Ser 630 residues. Additionally, our model
suggests a π-cation interaction between the 4,5-dichloro-1,2-phenylene
and nitrogen atoms from the arginine 125 residue, and π–π stacking
interaction between the phenyl ring from one salicylaldehyde moiety
and the tyrosine 666 residue. Finally, the interaction energies between
the enzyme residues and complex 1 indicate that Pro-109, Ile-107 and
Lys-463 interact eﬀectively with complex 1 (Fig. 2, and Table S3).
The simulated interaction between complex 2 and the active site of
the kinase domain of DPP-IV is shown in Fig. 3 and Fig. S5. Our cal-
culations suggest the presence of hydrogen bonds between the oxygens
from both salicylaldimine moieties and the Tyr 547 residue. Ad-
ditionally, there seem to be π–cation interactions (Arg 669 and 125,
respectively) and π–π stacking (Phe 357, His 740 and Tyr 547) between
the 4,5-dichloro-1,2-phenylene and one of the salicylaldimine moieties
of 2 and the active site of DPP-IV. Interaction energies between the
enzyme residues and complex 2 indicate eﬀective interaction with Pro-
109, Pro-159 and Ile-107 (Fig. 3 and Table S4).
3.7. Eﬀect of complexes 1 and 2 on blood glucose in alloxan -induced
diabetic mice
Complexes 1 and 2 were administered intragastricly to alloxan-
diabetic mice for 3 weeks. Metformin was used as positive control. This
drug is the only therapeutic agent that has been demonstrated to reduce
macrovascular events in type 2 diabetes [57]. The results showed that
complex 1 (22.5 mg V·kg−1; 198.8 mg·kg−1) and complex 2
(29.6 mg V·kg−1; 344.1 mg·kg−1) could signiﬁcantly lower the level of
serum glucose in the alloxan-diabetic mice (Fig. 4 and Table S5), when
compared with the diabetic control group (P < 0.05). After three
weeks of treatment, the extent of glucose reduction observed was
Fig.1. X-ray crystal structures of complexes 1 and 2 with atomic labelling scheme. Displacement ellipsoids are shown at the 30% probability level. The DMSO molecule in 2 has been
omitted.
Table 2
IC50 values (± SD) for inhibition of DPP-IV by oxidova-
nadium (IV) complexes.
Compound IC50 (μM)
1 38 ± 2
2 45 ± 3
Sitagliptina 0.018 ± 0.06
a Sitagliptin as a positive control was used to evaluate the
selected model.
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similar to the eﬀect produced by the treatment of mice with metformin
(250 mg·kg−1), although none of the compounds administered was able
to reduce blood glucose to the levels observed for non-diabetic mice
(Table S5). Throughout the experiment, there was no signiﬁcant dif-
ference in body weight among treated and control diabetic mice (Fig.
S6). This suggested that 1 and 2 were not toxic at the doses used.
These results are in agreement with evidence previously reported;
our compounds show moderate to low activity when compared with
similar complexes carrying chlorido substituents on ligands coordinated
to V [58–60].
4. Conclusions
Two oxidovanadium (IV) Schiﬀ base complexes with N,N′-1,2-phe-
nylenediamine -bis(salicyladimine) ligands carrying diﬀerent sub-
stituents were synthesised and evaluated as inhibitors of dipeptidyl
peptidase IV (DPP-IV) for the treatment of type 2 diabetes. The X-ray
structures of complexes 1 and 2 showed that the V(IV) is penta-
coordinate and in a distorted square-pyramidal environment. Both
complexes signiﬁcantly inhibit DPP-IV in vitro. Molecular modeling
shows that complexes 1 and 2 ﬁt well into the active-site cleft of the
kinase domain of DPP-IV. Moreover, in vivo tests show that 1
(22.5 mg V·kg−1) and 2 (29.6 mg V·kg−1) are as eﬀective in reducing
the levels of serum glucose in alloxan-diabetic mice as the clinical drug
metformin (250 mg·kg−1). However, oxidovanadium complexes are
known to degrade in the gastro-intestinal tract into insoluble and par-
tially soluble vanadate species (which are known phosphatase antago-
nists that can be used to treat diabetic symptoms). Therefore, further
experiments will be needed to determine if 1 and 2 can arrive intact in
the plasma of treated mice. Nevertheless, these results constitute the
ﬁrst report of vanadium complexes capable of inhibiting DPP-IV in vitro,
and provide an approach for exploring new design concepts for vana-
dium agents for incretin-based therapy.
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Fig. 2. Docking of 1 in the active site of the kinase domain
of DPP-IV. (a) Full view of 1 in DPP-IV with the complex
depicted in space-ﬁlling representation; (b) detailed illus-
tration of the surroundings near complex 1 in DPP-IV (DPP-
IV residues represented as sticks, 1 represented as ball and
sticks; O-red, N-blue, Cl-green, V-yellow).
Fig. 3. Docking of complex 2 in the active site of the kinase
domain of DPP-IV. (a) Full view of 2 in DPP-IV with the
complex depicted in space-ﬁlling representation; (b) de-
tailed illustration of the surroundings near complex 2 in
DPP-IV (DPP-IV residues represented as sticks, 1 re-
presented as ball and sticks; O-red, N-blue, Cl-green, V-
yellow).
Fig. 4. Eﬀects of intragastric administration of 1 and 2 on blood glucose levels in alloxan-
diabetic mice. The diabetic mice (DM) were induced by a single intraperitoneal injection
of alloxan 65 mg·kg−1. DM+Met group was treated with metformin at 250 mg·kg−1,
DM+ 1 group was treated with compound 1 at 22.5 mg V·kg−1, DM+ 2 group was
treated with compound 2 at 29.6 mg V·kg−1. The normal group (NOR) and DM group
were treated with saline. Data are expressed as mean ± standard deviations for 10 mice
in each group. ⁎P < 0.05 or less vs DM group; ⁎⁎P < 0.01 or less vs DM group (Dunnett's
test).
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Appendix A. Supplementary data
Crystallographic data for 1 and 2 have been deposited in the
Cambridge Crystallographic Data Centre (deposition numbers CCDC
1437003 and 1437007, respectively). Copies of these data can be ob-
tained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html
(or from the Cambridge Crystallographic Data Centre, 12, Union Road,
Cambridge CB21EZ, U.K.; fax: (+44) 1223-336-033; or desposit@ccdc.
cam.ac.uk). Supplementary data associated with this article can be
found in the online version, at http://dx.doi.org/10.1016/j.jinorgbio.
2017.06.014.
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